XML 49 R30.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Guarantor Financial Information | 12 Months Ended
--- | ---
Apr. 28, 2017
Condensed Financial Information of Parent Company Only Disclosure [Abstract] |
Guarantor Financial Information | Guarantor Financial Information On January 26, 2015, Medtronic plc and Medtronic Global Holdings S.C.A. (Medtronic Luxco), a wholly-owned subsidiary guarantor, each provided a full and unconditional guarantee of the obligations of Medtronic, Inc. under the Medtronic 2015 Senior Notes (Medtronic Senior Notes). In addition, Medtronic plc and Medtronic Luxco each provided a full and unconditional guarantee of the obligations of CIFSA, assumed as part of the Covidien acquisition, under the CIFSA Senior Notes. The guarantees of the CIFSA Senior Notes were in addition to the guarantees of the CIFSA Senior Notes by acquired Covidien holding companies Covidien Ltd. (formerly known as Covidien plc) and Covidien Group Holdings Ltd. (formerly known as Covidien Ltd.), both of which remain wholly-owned guarantors of the CIFSA Senior Notes. Medtronic Luxco issued two tranches of Senior Notes (Medtronic Luxco Senior Notes) in March 2017. Effective March 28, 2017, Medtronic plc and Medtronic, Inc. each provided a full and unconditional guarantee of the obligations of Medtronic Luxco under the Medtronic Luxco Senior Notes. A summary of the guarantees is as follows: Guarantees of Medtronic Senior Notes
• | Parent Company Guarantor - Medtronic plc
• | Subsidiary Issuer - Medtronic, Inc.
• | Subsidiary Guarantor - Medtronic Luxco
Guarantees of Medtronic Luxco Senior Notes
• | Parent Company Guarantor - Medtronic plc
• | Subsidiary Issuer - Medtronic Luxco
• | Subsidiary Guarantor - Medtronic, Inc.
Guarantees of CIFSA Senior Notes
• | Parent Company Guarantor - Medtronic plc
• | Subsidiary Issuer - CIFSA
• | Subsidiary Guarantors - Medtronic Luxco, Covidien Ltd., and Covidien Group Holdings Ltd. (CIFSA Subsidiary Guarantors)
The following presents the Company’s consolidating statements of comprehensive income and condensed consolidating statements of cash flows as of and for the fiscal years ended April 28, 2017, April 29, 2016, and April 24, 2015, and condensed consolidating balance sheets at April 28, 2017 and April 29, 2016. The guarantees provided by the Parent Company Guarantor and Subsidiary Guarantors are joint and several. Condensed consolidating financial information for Medtronic plc, Medtronic Luxco, Medtronic, Inc., CIFSA, and CIFSA Subsidiary Guarantors, on a stand-alone basis, is presented using the equity method of accounting for subsidiaries. During fiscal year 2017, the Company undertook certain steps to reorganize ownership of various subsidiaries. The transactions were entirely among subsidiaries under the common control of Medtronic. This reorganization has been reflected as of the beginning of the earliest period presented. The Company made revisions to its consolidating statements of comprehensive income of the guarantees of the Medtronic Senior Notes and CIFSA Senior notes as previously presented in Note 19 in the Company’s Annual Report on 10-K for fiscal year 2016 due to an incorrect presentation of the equity in net (income) loss of subsidiaries balances for the fiscal year ended April 29, 2016. In the consolidating statements of comprehensive income of the guarantees of the Medtronic Senior Notes, the $7.1 billion revision resulted in additional income reported in the equity in net (income) loss of subsidiaries line item in the Medtronic, Inc. column. In the consolidating statements of comprehensive income of the guarantees of the CIFSA Senior Notes, the $7.1 billion revision resulted in reduced income reported in the equity in net (income) loss of subsidiaries line item in the CIFSA column. There is no impact to the consolidated financial statements of Medtronic plc as previously filed in the 2016 Annual Report on Form 10-K or Quarterly Reports on Form 10-Q. The Company made revisions to its condensed consolidating balance sheets of the guarantees of the Medtronic Senior Notes and CIFSA Senior Notes as previously presented in Note 19 in the Company’s Annual Report on Form 10-K for fiscal year 2016 primarily due to an income statement error recognized in the second quarter of fiscal year 2016, resulting in an incorrect presentation of the investment in subsidiaries balances. In the condensed consolidating balance sheet of the guarantees of the Medtronic Senior Notes, the $5.1 billion revision increased the line items investment in subsidiaries and total equity in the Medtronic, Inc. column. In the condensed consolidating balance sheet of the guarantees of the CIFSA Senior Notes, the $5.1 billion revision decreased the line items investment in subsidiaries and total equity in the CIFSA column. There is no impact to the consolidated financial statements of Medtronic plc as previously filed in the 2016 Annual Report on Form 10-K or Quarterly Reports on Form 10-Q. The Company made revisions to the condensed consolidating balance sheets of the guarantees of the Medtronic Senior Notes and CIFSA Notes as previously presented in Note 19 in the Company’s Annual Report on Form 10-K for fiscal year 2016 due to an incorrect presentation of intercompany capital contributions. The $20.5 billion revision decreased the investment in subsidiaries and intercompany payable balances in the Medtronic plc column and decreased the investment in subsidiaries and total equity balances in the Medtronic Luxco and CIFSA Subsidiary Guarantors column in the condensed consolidating balance sheets of the guarantees of the Medtronic Senior Notes and CIFSA Senior Notes, respectively, decreased the intercompany receivable and total equity balances in Medtronic, Inc. column in the condensed consolidating balance sheets of the guarantees of the Medtronic Senior Notes, and decreased the intercompany receivable and total equity balances in the Subsidiary Non-Guarantors column. There is no impact to the consolidated financial statements of Medtronic plc as previously filed in the 2016 Annual Report on Form 10-K or Quarterly Reports on Form 10-Q. Consolidating Statement of Comprehensive Income Fiscal Year Ended April 28, 2017 Medtronic Senior Notes and Medtronic Luxco Senior Notes
(in millions) | Medtronic plc |  | Medtronic, Inc. |  | Medtronic Luxco |  | Subsidiary Non-guarantors |  | Consolidating Adjustments |  | Total
Net sales | $ | — |  |  | $ | 1,296 |  |  | $ | — |  |  | $ | 29,708 |  |  | $ | (1,294 | ) |  | $ | 29,710 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of products sold | — |  |  | 932 |  |  | — |  |  | 9,676 |  |  | (1,317 | ) |  | 9,291 |
Research and development expense | — |  |  | 636 |  |  | — |  |  | 1,557 |  |  | — |  |  | 2,193 |
Selling, general, and administrative expense | 12 |  |  | 1,163 |  |  | — |  |  | 8,536 |  |  | — |  |  | 9,711 |
Special charge (gain), net | — |  |  | 100 |  |  | — |  |  | — |  |  | — |  |  | 100 |
Restructuring charges, net | — |  |  | 114 |  |  | — |  |  | 249 |  |  | — |  |  | 363 |
Certain litigation charges | — |  |  | — |  |  | — |  |  | 300 |  |  | — |  |  | 300 |
Acquisition-related items | — |  |  | 133 |  |  | — |  |  | 87 |  |  | — |  |  | 220 |
Amortization of intangible assets | — |  |  | 11 |  |  | — |  |  | 1,969 |  |  | — |  |  | 1,980 |
Other expense (income), net | 18 |  |  | (2,954 | ) |  | — |  |  | 3,158 |  |  | — |  |  | 222 |
Operating (loss) profit | (30 | ) |  | 1,161 |  |  | — |  |  | 4,176 |  |  | 23 |  |  | 5,330 |
Interest income | — |  |  | (250 | ) |  | (649 | ) |  | (1,065 | ) |  | 1,598 |  |  | (366 | )
Interest expense | 113 |  |  | 1,652 |  |  | 62 |  |  | 865 |  |  | (1,598 | ) |  | 1,094 |
Interest expense (income), net | 113 |  |  | 1,402 |  |  | (587 | ) |  | (200 | ) |  | — |  |  | 728 |
Equity in net (income) loss of subsidiaries | (4,163 | ) |  | (2,484 | ) |  | (3,576 | ) |  | — |  |  | 10,223 |  |  | — |
Income (loss) from operations before income taxes | 4,020 |  |  | 2,243 |  |  | 4,163 |  |  | 4,376 |  |  | (10,200 | ) |  | 4,602 |
Provision (benefit) for income taxes | (8 | ) |  | (1 | ) |  | — |  |  | 587 |  |  | — |  |  | 578 |
Net income | 4,028 |  |  | 2,244 |  |  | 4,163 |  |  | 3,789 |  |  | (10,200 | ) |  | 4,024 |
Net loss attributable to noncontrolling interests | — |  |  | — |  |  | — |  |  | 4 |  |  | — |  |  | 4 |
Net income attributable to Medtronic | 4,028 |  |  | 2,244 |  |  | 4,163 |  |  | 3,793 |  |  | (10,200 | ) |  | 4,028 |
Other comprehensive (loss) income, net of tax | (745 | ) |  | 111 |  |  | (745 | ) |  | (928 | ) |  | 1,563 |  |  | (744 | )
Other comprehensive loss attributable to non-controlling interests | — |  |  | — |  |  | — |  |  | 3 |  |  | — |  |  | 3 |
Total comprehensive income (loss) attributable to Medtronic | $ | 3,283 |  |  | $ | 2,355 |  |  | $ | 3,418 |  |  | $ | 2,864 |  |  | $ | (8,637 | ) |  | $ | 3,283 |
Consolidating Statement of Comprehensive Income Fiscal Year Ended April 29, 2016 Medtronic Senior Notes
(in millions) | Medtronic plc |  | Medtronic, Inc. |  | Medtronic Luxco |  | Subsidiary Non-guarantors |  | Consolidating Adjustments |  | Total
Net sales | $ | — |  |  | $ | 1,411 |  |  | $ | — |  |  | $ | 28,832 |  |  | $ | (1,410 | ) |  | $ | 28,833 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of products sold | — |  |  | 991 |  |  | — |  |  | 9,561 |  |  | (1,410 | ) |  | 9,142 |
Research and development expense | — |  |  | 627 |  |  | — |  |  | 1,597 |  |  | — |  |  | 2,224 |
Selling, general, and administrative expense | 10 |  |  | 991 |  |  | — |  |  | 8,468 |  |  | — |  |  | 9,469 |
Special charge (gain), net | — |  |  | 70 |  |  | — |  |  | — |  |  | — |  |  | 70 |
Restructuring charges, net | — |  |  | 17 |  |  | — |  |  | 273 |  |  | — |  |  | 290 |
Certain litigation charges | — |  |  | — |  |  | — |  |  | 26 |  |  | — |  |  | 26 |
Acquisition-related items | — |  |  | 135 |  |  | — |  |  | 148 |  |  | — |  |  | 283 |
Amortization of intangible assets | — |  |  | 12 |  |  | — |  |  | 1,919 |  |  | — |  |  | 1,931 |
Other expense (income), net | 112 |  |  | (2,329 | ) |  | — |  |  | 2,324 |  |  | — |  |  | 107 |
Operating (loss) profit | (122 | ) |  | 897 |  |  | — |  |  | 4,516 |  |  | — |  |  | 5,291 |
Interest income | — |  |  | (237 | ) |  | (706 | ) |  | (448 | ) |  | 960 |  |  | (431 | )
Interest expense | 25 |  |  | 1,906 |  |  | 10 |  |  | 405 |  |  | (960 | ) |  | 1,386 |
Interest expense (income), net | 25 |  |  | 1,669 |  |  | (696 | ) |  | (43 | ) |  | — |  |  | 955 |
Equity in net (income) loss of subsidiaries | (3,676 | ) |  | (2,447 | ) |  | (2,980 | ) |  | — |  |  | 9,103 |  |  | — |
Income (loss) from operations before income taxes | 3,529 |  |  | 1,675 |  |  | 3,676 |  |  | 4,559 |  |  | (9,103 | ) |  | 4,336 |
Provision (benefit) for income taxes | (9 | ) |  | (96 | ) |  | — |  |  | 903 |  |  | — |  |  | 798 |
Net income | 3,538 |  |  | 1,771 |  |  | 3,676 |  |  | 3,656 |  |  | (9,103 | ) |  | 3,538 |
Other comprehensive (loss) income, net of tax | (684 | ) |  | (493 | ) |  | (684 | ) |  | (673 | ) |  | 1,850 |  |  | (684 | )
Total comprehensive income (loss) | $ | 2,854 |  |  | $ | 1,278 |  |  | $ | 2,992 |  |  | $ | 2,983 |  |  | $ | (7,253 | ) |  | $ | 2,854 |
Consolidating Statement of Comprehensive Income Fiscal Year Ended April 24, 2015 Medtronic Senior Notes
(in millions) | Medtronic plc |  | Medtronic, Inc. |  | Medtronic Luxco |  | Subsidiary Non-guarantors |  | Consolidating Adjustments |  | Total
Net sales | $ | — |  |  | $ | 1,261 |  |  | $ | — |  |  | $ | 20,261 |  |  | $ | (1,261 | ) |  | $ | 20,261 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of products sold | — |  |  | 895 |  |  | — |  |  | 6,659 |  |  | (1,245 | ) |  | 6,309 |
Research and development expense | — |  |  | 552 |  |  | — |  |  | 1,088 |  |  | — |  |  | 1,640 |
Selling, general, and administrative expense | 1 |  |  | 857 |  |  | — |  |  | 6,046 |  |  | — |  |  | 6,904 |
Special charge (gain), net | — |  |  | 100 |  |  | — |  |  | (138 | ) |  | — |  |  | (38 | )
Restructuring charges, net | — |  |  | 7 |  |  | — |  |  | 230 |  |  | — |  |  | 237 |
Certain litigation charges | — |  |  | — |  |  | — |  |  | 42 |  |  | — |  |  | 42 |
Acquisition-related items | — |  |  | 312 |  |  | — |  |  | 238 |  |  | — |  |  | 550 |
Amortization of intangible assets | — |  |  | 11 |  |  | — |  |  | 722 |  |  | — |  |  | 733 |
Other expense (income), net | 103 |  |  | (1,618 | ) |  | — |  |  | 1,633 |  |  | — |  |  | 118 |
Operating (loss) profit | (104 | ) |  | 145 |  |  | — |  |  | 3,741 |  |  | (16 | ) |  | 3,766 |
Interest income | — |  |  | (56 | ) |  | (170 | ) |  | (387 | ) |  | 227 |  |  | (386 | )
Interest expense | — |  |  | 762 |  |  | — |  |  | 131 |  |  | (227 | ) |  | 666 |
Interest expense (income), net | — |  |  | 706 |  |  | (170 | ) |  | (256 | ) |  | — |  |  | 280 |
Equity in net (income) loss of subsidiaries | (2,790 | ) |  | (5,500 | ) |  | (2,620 | ) |  | — |  |  | 10,910 |  |  | — |
Income (loss) from operations before income taxes | 2,686 |  |  | 4,939 |  |  | 2,790 |  |  | 3,997 |  |  | (10,926 | ) |  | 3,486 |
Provision (benefit) for income taxes | 11 |  |  | (44 | ) |  | — |  |  | 844 |  |  | — |  |  | 811 |
Net income | 2,675 |  |  | 4,983 |  |  | 2,790 |  |  | 3,153 |  |  | (10,926 | ) |  | 2,675 |
Other comprehensive income (loss), net of tax | (587 | ) |  | (542 | ) |  | (587 | ) |  | (232 | ) |  | 1,361 |  |  | (587 | )
Total comprehensive income (loss) | $ | 2,088 |  |  | $ | 4,441 |  |  | $ | 2,203 |  |  | $ | 2,921 |  |  | $ | (9,565 | ) |  | $ | 2,088 |
Condensed Consolidating Balance Sheet April 28, 2017 Medtronic Senior Notes and Medtronic Luxco Senior Notes
(in millions) | Medtronic plc |  | Medtronic, Inc. |  | Medtronic Luxco |  | Subsidiary Non-guarantors |  | Consolidating Adjustments |  | Total
ASSETS |  |  |  |  |  |  |  |  |  |  |
Current assets: |  |  |  |  |  |  |  |  |  |  |
Cash and cash equivalents | $ | — |  |  | $ | 45 |  |  | $ | 5 |  |  | $ | 4,917 |  |  | $ | — |  |  | $ | 4,967 |
Investments | — |  |  | — |  |  | — |  |  | 8,741 |  |  | — |  |  | 8,741 |
Accounts receivable, net | — |  |  | — |  |  | — |  |  | 5,591 |  |  | — |  |  | 5,591 |
Inventories, net | — |  |  | 155 |  |  | — |  |  | 3,361 |  |  | (178 | ) |  | 3,338 |
Intercompany receivable | 63 |  |  | — |  |  | — |  |  | 12,618 |  |  | (12,681 | ) |  | — |
Prepaid expenses and other current assets | 10 |  |  | 227 |  |  | — |  |  | 1,628 |  |  | — |  |  | 1,865 |
Current assets held for sale | — |  |  | — |  |  | — |  |  | 371 |  |  | — |  |  | 371 |
Total current assets | 73 |  |  | 427 |  |  | 5 |  |  | 37,227 |  |  | (12,859 | ) |  | 24,873 |
Property, plant and equipment, net | — |  |  | 1,311 |  |  | — |  |  | 3,050 |  |  | — |  |  | 4,361 |
Goodwill | — |  |  | — |  |  | — |  |  | 38,515 |  |  | — |  |  | 38,515 |
Other intangible assets, net | — |  |  | 20 |  |  | — |  |  | 23,387 |  |  | — |  |  | 23,407 |
Tax assets | — |  |  | 727 |  |  | — |  |  | 782 |  |  | — |  |  | 1,509 |
Investment in subsidiaries | 55,833 |  |  | 71,931 |  |  | 52,618 |  |  | — |  |  | (180,382 | ) |  | — |
Intercompany loans receivable | 3,000 |  |  | 12,162 |  |  | 16,114 |  |  | 32,774 |  |  | (64,050 | ) |  | — |
Other assets | — |  |  | 434 |  |  | — |  |  | 798 |  |  | — |  |  | 1,232 |
Noncurrent assets held for sale | — |  |  | — |  |  | — |  |  | 5,919 |  |  | — |  |  | 5,919 |
Total assets | $ | 58,906 |  |  | $ | 87,012 |  |  | $ | 68,737 |  |  | $ | 142,452 |  |  | $ | (257,291 | ) |  | $ | 99,816 |
LIABILITIES AND EQUITY |  |  |  |  |  |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |  |  |  |  |  |
Current debt obligations | $ | — |  |  | $ | 5,000 |  |  | $ | 901 |  |  | $ | 1,619 |  |  | $ | — |  |  | $ | 7,520 |
Accounts payable | — |  |  | 304 |  |  | — |  |  | 1,427 |  |  | — |  |  | 1,731 |
Intercompany payable | 12 |  |  | 12,669 |  |  | — |  |  | — |  |  | (12,681 | ) |  | — |
Accrued compensation | 9 |  |  | 734 |  |  | — |  |  | 1,117 |  |  | — |  |  | 1,860 |
Accrued income taxes | 13 |  |  | — |  |  | — |  |  | 620 |  |  | — |  |  | 633 |
Other accrued expenses | — |  |  | 352 |  |  | 4 |  |  | 2,086 |  |  | — |  |  | 2,442 |
Current liabilities held for sale | — |  |  | — |  |  | — |  |  | 34 |  |  | — |  |  | 34 |
Total current liabilities | 34 |  |  | 19,059 |  |  | 905 |  |  | 6,903 |  |  | (12,681 | ) |  | 14,220 |
Long-term debt | — |  |  | 21,782 |  |  | 1,842 |  |  | 2,297 |  |  | — |  |  | 25,921 |
Accrued compensation and retirement benefits | — |  |  | 1,120 |  |  | — |  |  | 521 |  |  | — |  |  | 1,641 |
Accrued income taxes | 10 |  |  | 1,658 |  |  | — |  |  | 737 |  |  | — |  |  | 2,405 |
Intercompany loans payable | 8,568 |  |  | 13,151 |  |  | 17,160 |  |  | 25,171 |  |  | (64,050 | ) |  | — |
Deferred tax liabilities | — |  |  | — |  |  | — |  |  | 2,978 |  |  | — |  |  | 2,978 |
Other liabilities | — |  |  | 153 |  |  | — |  |  | 1,362 |  |  | — |  |  | 1,515 |
Noncurrent liabilities held for sale | — |  |  | — |  |  | — |  |  | 720 |  |  | — |  |  | 720 |
Total liabilities | 8,612 |  |  | 56,923 |  |  | 19,907 |  |  | 40,689 |  |  | (76,731 | ) |  | 49,400 |
Shareholders’ equity | 50,294 |  |  | 30,089 |  |  | 48,830 |  |  | 101,641 |  |  | (180,560 | ) |  | 50,294 |
Noncontrolling interests | — |  |  | — |  |  | — |  |  | 122 |  |  | — |  |  | 122 |
Total equity | 50,294 |  |  | 30,089 |  |  | 48,830 |  |  | 101,763 |  |  | (180,560 | ) |  | 50,416 |
Total liabilities and equity | $ | 58,906 |  |  | $ | 87,012 |  |  | $ | 68,737 |  |  | $ | 142,452 |  |  | $ | (257,291 | ) |  | $ | 99,816 |
Condensed Consolidating Balance Sheet April 29, 2016 Medtronic Senior Notes
(in millions) | Medtronic plc |  | Medtronic, Inc. |  | Medtronic Luxco |  | Subsidiary Non-guarantors |  | Consolidating Adjustments |  | Total
ASSETS |  |  |  |  |  |  |  |  |  |  |
Current assets: |  |  |  |  |  |  |  |  |  |  |
Cash and cash equivalents | $ | — |  |  | $ | 55 |  |  | $ | — |  |  | $ | 2,821 |  |  | $ | — |  |  | $ | 2,876 |
Investments | — |  |  | — |  |  | — |  |  | 9,758 |  |  | — |  |  | 9,758 |
Accounts receivable, net | — |  |  | — |  |  | — |  |  | 5,562 |  |  | — |  |  | 5,562 |
Inventories, net | — |  |  | 162 |  |  | — |  |  | 3,511 |  |  | (200 | ) |  | 3,473 |
Intercompany receivable | 403 |  |  | 141,368 |  |  | — |  |  | 162,278 |  |  | (304,049 | ) |  | — |
Prepaid expenses and other current assets | 24 |  |  | 271 |  |  | — |  |  | 1,636 |  |  | — |  |  | 1,931 |
Total current assets | 427 |  |  | 141,856 |  |  | — |  |  | 185,566 |  |  | (304,249 | ) |  | 23,600 |
Property, plant and equipment, net | — |  |  | 1,139 |  |  | — |  |  | 3,702 |  |  | — |  |  | 4,841 |
Goodwill | — |  |  | — |  |  | — |  |  | 41,500 |  |  | — |  |  | 41,500 |
Other intangible assets, net | — |  |  | 31 |  |  | — |  |  | 26,868 |  |  | — |  |  | 26,899 |
Tax assets | — |  |  | 690 |  |  | — |  |  | 693 |  |  | — |  |  | 1,383 |
Investment in subsidiaries | 52,608 |  |  | 68,903 |  |  | 49,698 |  |  | — |  |  | (171,209 | ) |  | — |
Intercompany loans receivable | 3,000 |  |  | 8,884 |  |  | 10,203 |  |  | 18,140 |  |  | (40,227 | ) |  | — |
Other assets | — |  |  | 506 |  |  | — |  |  | 915 |  |  | — |  |  | 1,421 |
Total assets | $ | 56,035 |  |  | $ | 222,009 |  |  | $ | 59,901 |  |  | $ | 277,384 |  |  | $ | (515,685 | ) |  | $ | 99,644 |
LIABILITIES AND EQUITY |  |  |  |  |  |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |  |  |  |  |  |
Current debt obligations | $ | — |  |  | $ | 500 |  |  | $ | — |  |  | $ | 493 |  |  | $ | — |  |  | $ | 993 |
Accounts payable | — |  |  | 288 |  |  | — |  |  | 1,421 |  |  | — |  |  | 1,709 |
Intercompany payable | — |  |  | 151,687 |  |  | — |  |  | 152,362 |  |  | (304,049 | ) |  | — |
Accrued compensation | 32 |  |  | 616 |  |  | — |  |  | 1,064 |  |  | — |  |  | 1,712 |
Accrued income taxes | 11 |  |  | — |  |  | — |  |  | 555 |  |  | — |  |  | 566 |
Other accrued expenses | 1 |  |  | 243 |  |  | — |  |  | 1,941 |  |  | — |  |  | 2,185 |
Total current liabilities | 44 |  |  | 153,334 |  |  | — |  |  | 157,836 |  |  | (304,049 | ) |  | 7,165 |
Long-term debt | — |  |  | 26,646 |  |  | — |  |  | 3,463 |  |  | — |  |  | 30,109 |
Accrued compensation and retirement benefits | — |  |  | 1,258 |  |  | — |  |  | 501 |  |  | — |  |  | 1,759 |
Accrued income taxes | 10 |  |  | 1,422 |  |  | — |  |  | 1,471 |  |  | — |  |  | 2,903 |
Intercompany loans payable | 3,918 |  |  | 10,128 |  |  | 14,297 |  |  | 11,884 |  |  | (40,227 | ) |  | — |
Deferred tax liabilities | — |  |  | — |  |  | — |  |  | 3,729 |  |  | — |  |  | 3,729 |
Other liabilities | — |  |  | 202 |  |  | — |  |  | 1,714 |  |  | — |  |  | 1,916 |
Total liabilities | 3,972 |  |  | 192,990 |  |  | 14,297 |  |  | 180,598 |  |  | (344,276 | ) |  | 47,581 |
Total equity | 52,063 |  |  | 29,019 |  |  | 45,604 |  |  | 96,786 |  |  | (171,409 | ) |  | 52,063 |
Total liabilities and equity | $ | 56,035 |  |  | $ | 222,009 |  |  | $ | 59,901 |  |  | $ | 277,384 |  |  | $ | (515,685 | ) |  | $ | 99,644 |
Condensed Consolidating Statement of Cash Flows Fiscal Year Ended April 28, 2017 Medtronic Senior Notes and Medtronic Luxco Senior Notes
(in millions) | Medtronic plc |  | Medtronic, Inc. |  | Medtronic Luxco |  | Subsidiary Non-guarantors |  | Consolidating Adjustments |  | Total
Operating Activities: |  |  |  |  |  |  |  |  |  |  |
Net cash provided by operating activities | $ | 842 |  |  | $ | 1,902 |  |  | $ | 302 |  |  | $ | 4,721 |  |  | $ | (887 | ) |  | $ | 6,880 |
Investing Activities: |  |  |  |  |  |  |  |  |  |  |
Acquisitions, net of cash acquired | — |  |  | (940 | ) |  | — |  |  | (384 | ) |  | — |  |  | (1,324 | )
Additions to property, plant, and equipment | — |  |  | (369 | ) |  | — |  |  | (885 | ) |  | — |  |  | (1,254 | )
Purchases of investments | — |  |  | — |  |  | — |  |  | (4,533 | ) |  | 162 |  |  | (4,371 | )
Sales and maturities of investments | — |  |  | 210 |  |  | — |  |  | 5,308 |  |  | (162 | ) |  | 5,356 |
Net (increase) decrease in intercompany loans receivable | — |  |  | (3,278 | ) |  | (5,911 | ) |  | (4,624 | ) |  | 13,813 |  |  | — |
Capital contributions paid | — |  |  | (248 | ) |  | — |  |  | — |  |  | 248 |  |  | — |
Other investing activities, net | — |  |  | — |  |  | — |  |  | 22 |  |  | — |  |  | 22 |
Net cash (used in) provided by investing activities | — |  |  | (4,625 | ) |  | (5,911 | ) |  | (5,096 | ) |  | 14,061 |  |  | (1,571 | )
Financing Activities: |  |  |  |  |  |  |  |  |  |  |
Acquisition-related contingent consideration | — |  |  | — |  |  | — |  |  | (69 | ) |  | — |  |  | (69 | )
Change in current debt obligations, net | — |  |  | — |  |  | 901 |  |  | 5 |  |  | — |  |  | 906 |
Repayment of short-term borrowings (maturities greater than 90 days) | — |  |  | — |  |  | — |  |  | (2 | ) |  | — |  |  | (2 | )
Proceeds from short-term borrowings (maturities greater than 90 days) | — |  |  | — |  |  | — |  |  | 12 |  |  | — |  |  | 12 |
Issuance of long-term debt | — |  |  | 150 |  |  | 1,850 |  |  | 140 |  |  | — |  |  | 2,140 |
Payments on long-term debt | — |  |  | (500 | ) |  | — |  |  | (363 | ) |  | — |  |  | (863 | )
Dividends to shareholders | (2,376 | ) |  | — |  |  | — |  |  | — |  |  | — |  |  | (2,376 | )
Issuance of ordinary shares | 428 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 428 |
Repurchase of ordinary shares | (3,544 | ) |  | — |  |  | — |  |  | — |  |  | — |  |  | (3,544 | )
Net intercompany loan borrowings (repayments) | 4,650 |  |  | 3,023 |  |  | 2,863 |  |  | 3,277 |  |  | (13,813 | ) |  | — |
Intercompany dividends paid | — |  |  | — |  |  | — |  |  | (887 | ) |  | 887 |  |  | — |
Capital contributions received | — |  |  | — |  |  | — |  |  | 248 |  |  | (248 | ) |  | — |
Other financing activities | — |  |  | 40 |  |  | — |  |  | 45 |  |  | — |  |  | 85 |
Net cash (used in) provided by financing activities | (842 | ) |  | 2,713 |  |  | 5,614 |  |  | 2,406 |  |  | (13,174 | ) |  | (3,283 | )
Effect of exchange rate changes on cash and cash equivalents | — |  |  | — |  |  | — |  |  | 65 |  |  | — |  |  | 65 |
Net change in cash and cash equivalents | — |  |  | (10 | ) |  | 5 |  |  | 2,096 |  |  | — |  |  | 2,091 |
Cash and cash equivalents at beginning of period | — |  |  | 55 |  |  | — |  |  | 2,821 |  |  | — |  |  | 2,876 |
Cash and cash equivalents at end of period | $ | — |  |  | $ | 45 |  |  | $ | 5 |  |  | $ | 4,917 |  |  | $ | — |  |  | $ | 4,967 |
Condensed Consolidating Statement of Cash Flows Fiscal Year Ended April 29, 2016 Medtronic Senior Notes
(in millions) | Medtronic plc |  | Medtronic, Inc. |  | Medtronic Luxco |  | Subsidiary Non-guarantors |  | Consolidating Adjustments |  | Total
Operating Activities: |  |  |  |  |  |  |  |  |  |  |
Net cash provided by operating activities | $ | 297 |  |  | $ | 402 |  |  | $ | 696 |  |  | $ | 4,635 |  |  | $ | (812 | ) |  | $ | 5,218 |
Investing Activities: |  |  |  |  |  |  |  |  |  |  |
Acquisitions, net of cash acquired | — |  |  | (526 | ) |  | — |  |  | (687 | ) |  | — |  |  | (1,213 | )
Additions to property, plant, and equipment | — |  |  | (334 | ) |  | — |  |  | (712 | ) |  | — |  |  | (1,046 | )
Purchases of investments | — |  |  | — |  |  | — |  |  | (5,406 | ) |  | — |  |  | (5,406 | )
Sales and maturities of investments | — |  |  | — |  |  | — |  |  | 9,924 |  |  | — |  |  | 9,924 |
Net (increase) decrease in intercompany loans receivable | — |  |  | (2,368 | ) |  | (203 | ) |  | (7,921 | ) |  | 10,492 |  |  | — |
Capital contributions paid | — |  |  | (11 | ) |  | (4,959 | ) |  | (4,900 | ) |  | 9,870 |  |  | — |
Other investing activities, net | — |  |  | — |  |  | — |  |  | (14 | ) |  | — |  |  | (14 | )
Net cash (used in) provided by investing activities | — |  |  | (3,239 | ) |  | (5,162 | ) |  | (9,716 | ) |  | 20,362 |  |  | 2,245 |
Financing Activities: |  |  |  |  |  |  |  |  |  |  |
Acquisition-related contingent consideration | — |  |  | — |  |  | — |  |  | (22 | ) |  | — |  |  | (22 | )
Change in current debt obligations, net | — |  |  | — |  |  | — |  |  | 7 |  |  | — |  |  | 7 |
Repayment of short-term borrowings (maturities greater than 90 days) | — |  |  | — |  |  | (139 | ) |  | — |  |  | — |  |  | (139 | )
Proceeds from short-term borrowings (maturities greater than 90 days) | — |  |  | — |  |  | 139 |  |  | — |  |  | — |  |  | 139 |
Payments on long-term debt | — |  |  | (2,988 | ) |  | — |  |  | (2,144 | ) |  | — |  |  | (5,132 | )
Dividends to shareholders | (2,139 | ) |  | — |  |  | — |  |  | — |  |  | — |  |  | (2,139 | )
Issuance of ordinary shares | 491 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 491 |
Repurchase of ordinary shares | (2,830 | ) |  | — |  |  | — |  |  | — |  |  | — |  |  | (2,830 | )
Net intercompany loan borrowings (repayments) | 3,918 |  |  | (91 | ) |  | 4,296 |  |  | 2,369 |  |  | (10,492 | ) |  | — |
Intercompany dividends paid | — |  |  | — |  |  | — |  |  | (812 | ) |  | 812 |  |  | — |
Capital contributions received | — |  |  | 4,900 |  |  | — |  |  | 4,970 |  |  | (9,870 | ) |  | — |
Other financing activities | — |  |  | — |  |  | — |  |  | 82 |  |  | — |  |  | 82 |
Net cash (used in) provided by financing activities | (560 | ) |  | 1,821 |  |  | 4,296 |  |  | 4,450 |  |  | (19,550 | ) |  | (9,543 | )
Effect of exchange rate changes on cash and cash equivalents | — |  |  | — |  |  | — |  |  | 113 |  |  | — |  |  | 113 |
Net change in cash and cash equivalents | (263 | ) |  | (1,016 | ) |  | (170 | ) |  | (518 | ) |  | — |  |  | (1,967 | )
Cash and cash equivalents at beginning of period | 263 |  |  | 1,071 |  |  | 170 |  |  | 3,339 |  |  | — |  |  | 4,843 |
Cash and cash equivalents at end of period | $ | — |  |  | $ | 55 |  |  | $ | — |  |  | $ | 2,821 |  |  | $ | — |  |  | $ | 2,876 |
Condensed Consolidating Statement of Cash Flows Fiscal Year Ended April 24, 2015 Medtronic Senior Notes
(in millions) | Medtronic plc |  | Medtronic, Inc. |  | Medtronic Luxco |  | Subsidiary Non-guarantors |  | Consolidating Adjustments |  | Total
Operating Activities: |  |  |  |  |  |  |  |  |  |  |
Net cash provided by operating activities | $ | 26 |  |  | $ | 1,479 |  |  | $ | 170 |  |  | $ | 3,640 |  |  | $ | (413 | ) |  | $ | 4,902 |
Investing Activities: |  |  |  |  |  |  |  |  |  |  |
Acquisitions, net of cash acquired | (9,700 | ) |  | (65 | ) |  | — |  |  | (5,119 | ) |  | — |  |  | (14,884 | )
Additions to property, plant, and equipment | — |  |  | (187 | ) |  | — |  |  | (384 | ) |  | — |  |  | (571 | )
Purchases of investments | — |  |  | — |  |  | — |  |  | (7,582 | ) |  | — |  |  | (7,582 | )
Sales and maturities of investments | — |  |  | — |  |  | — |  |  | 5,890 |  |  | — |  |  | 5,890 |
Net (increase) decrease in intercompany loans receivable | — |  |  | (16,996 | ) |  | — |  |  | 53 |  |  | 16,943 |  |  | — |
Other investing activities, net | — |  |  | — |  |  | — |  |  | 89 |  |  | — |  |  | 89 |
Net cash (used in) provided by investing activities | (9,700 | ) |  | (17,248 | ) |  | — |  |  | (7,053 | ) |  | 16,943 |  |  | (17,058 | )
Financing Activities: |  |  |  |  |  |  |  |  |  |  |
Acquisition-related contingent consideration | — |  |  | — |  |  | — |  |  | (85 | ) |  | — |  |  | (85 | )
Change in current debt obligations, net | — |  |  | — |  |  | — |  |  | (1 | ) |  | — |  |  | (1 | )
Repayment of short-term borrowings (maturities greater than 90 days) | — |  |  | (150 | ) |  | — |  |  | — |  |  | — |  |  | (150 | )
Proceeds from short-term borrowings (maturities greater than 90 days) | — |  |  | 150 |  |  | — |  |  | — |  |  | — |  |  | 150 |
Issuance of long-term debt | — |  |  | 19,942 |  |  | — |  |  | — |  |  | — |  |  | 19,942 |
Payments on long-term debt | — |  |  | (1,268 | ) |  | — |  |  | — |  |  | — |  |  | (1,268 | )
Dividends to shareholders | (435 | ) |  | (902 | ) |  | — |  |  | — |  |  | — |  |  | (1,337 | )
Issuance of ordinary shares | 172 |  |  | 477 |  |  | — |  |  | — |  |  | — |  |  | 649 |
Repurchase of ordinary shares | (300 | ) |  | (1,620 | ) |  | — |  |  | — |  |  | — |  |  | (1,920 | )
Net intercompany loan borrowings (repayments) | 10,500 |  |  | (53 | ) |  | — |  |  | 6,496 |  |  | (16,943 | ) |  | — |
Intercompany dividends paid | — |  |  | — |  |  | — |  |  | (413 | ) |  | 413 |  |  | — |
Other financing activities | — |  |  | — |  |  | — |  |  | (31 | ) |  | — |  |  | (31 | )
Net cash (used in) provided by financing activities | 9,937 |  |  | 16,576 |  |  | — |  |  | 5,966 |  |  | (16,530 | ) |  | 15,949 |
Effect of exchange rate changes on cash and cash equivalents | — |  |  | — |  |  | — |  |  | (353 | ) |  | — |  |  | (353 | )
Net change in cash and cash equivalents | 263 |  |  | 807 |  |  | 170 |  |  | 2,200 |  |  | — |  |  | 3,440 |
Cash and cash equivalents at beginning of period | — |  |  | 264 |  |  | — |  |  | 1,139 |  |  | — |  |  | 1,403 |
Cash and cash equivalents at end of period | $ | 263 |  |  | $ | 1,071 |  |  | $ | 170 |  |  | $ | 3,339 |  |  | $ | — |  |  | $ | 4,843 |
Consolidating Statement of Comprehensive Income Fiscal Year Ended April 28, 2017 CIFSA Senior Notes
(in millions) | Medtronic plc |  | CIFSA |  | CIFSA Subsidiary Guarantors |  | Subsidiary Non-guarantors |  | Consolidating Adjustments |  | Total
Net sales | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 29,710 |  |  | $ | — |  |  | $ | 29,710 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of products sold | — |  |  | — |  |  | — |  |  | 9,291 |  |  | — |  |  | 9,291 |
Research and development expense | — |  |  | — |  |  | — |  |  | 2,193 |  |  | — |  |  | 2,193 |
Selling, general, and administrative expense | 12 |  |  | 1 |  |  | 2 |  |  | 9,696 |  |  | — |  |  | 9,711 |
Special charge (gain), net | — |  |  | — |  |  | — |  |  | 100 |  |  | — |  |  | 100 |
Restructuring charges, net | — |  |  | — |  |  | — |  |  | 363 |  |  | — |  |  | 363 |
Certain litigation charges | — |  |  | — |  |  | — |  |  | 300 |  |  | — |  |  | 300 |
Acquisition-related items | — |  |  | — |  |  | — |  |  | 220 |  |  | — |  |  | 220 |
Amortization of intangible assets | — |  |  | — |  |  | — |  |  | 1,980 |  |  | — |  |  | 1,980 |
Other expense (income), net | 18 |  |  | 1 |  |  | 4 |  |  | 199 |  |  | — |  |  | 222 |
Operating (loss) profit | (30 | ) |  | (2 | ) |  | (6 | ) |  | 5,368 |  |  | — |  |  | 5,330 |
Interest income | — |  |  | (82 | ) |  | (656 | ) |  | (433 | ) |  | 805 |  |  | (366 | )
Interest expense | 113 |  |  | 104 |  |  | 62 |  |  | 1,620 |  |  | (805 | ) |  | 1,094 |
Interest expense (income), net | 113 |  |  | 22 |  |  | (594 | ) |  | 1,187 |  |  | — |  |  | 728 |
Equity in net (income) loss of subsidiaries | (4,163 | ) |  | (2,329 | ) |  | (3,575 | ) |  | — |  |  | 10,067 |  |  | — |
Income (loss) from operations before income taxes | 4,020 |  |  | 2,305 |  |  | 4,163 |  |  | 4,181 |  |  | (10,067 | ) |  | 4,602 |
Provision (benefit) for income taxes | (8 | ) |  | — |  |  | — |  |  | 586 |  |  | — |  |  | 578 |
Net income | 4,028 |  |  | 2,305 |  |  | 4,163 |  |  | 3,595 |  |  | (10,067 | ) |  | 4,024 |
Net loss attributable to noncontrolling interests | — |  |  | — |  |  | — |  |  | 4 |  |  | — |  |  | 4 |
Net income attributable to Medtronic | 4,028 |  |  | 2,305 |  |  | 4,163 |  |  | 3,599 |  |  | (10,067 | ) |  | 4,028 |
Other comprehensive (loss) income, net of tax | (745 | ) |  | (84 | ) |  | (745 | ) |  | (744 | ) |  | 1,574 |  |  | (744 | )
Other comprehensive loss attributable to non-controlling interests | — |  |  | — |  |  | — |  |  | 3 |  |  | — |  |  | 3 |
Total comprehensive income (loss) attributable to Medtronic | $ | 3,283 |  |  | $ | 2,221 |  |  | $ | 3,418 |  |  | $ | 2,854 |  |  | $ | (8,493 | ) |  | $ | 3,283 |
Consolidating Statement of Comprehensive Income Fiscal Year Ended April 29, 2016 CIFSA Senior Notes
(in millions) | Medtronic plc |  | CIFSA |  | CIFSA Subsidiary Guarantors |  | Subsidiary Non-guarantors |  | Consolidating Adjustments |  | Total
Net sales | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 28,833 |  |  | $ | — |  |  | $ | 28,833 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of products sold | — |  |  | — |  |  | — |  |  | 9,142 |  |  | — |  |  | 9,142 |
Research and development expense | — |  |  | — |  |  | — |  |  | 2,224 |  |  | — |  |  | 2,224 |
Selling, general, and administrative expense | 10 |  |  | 1 |  |  | 3 |  |  | 9,455 |  |  | — |  |  | 9,469 |
Special charge (gain), net | — |  |  | — |  |  | — |  |  | 70 |  |  | — |  |  | 70 |
Restructuring charges, net | — |  |  | — |  |  | — |  |  | 290 |  |  | — |  |  | 290 |
Certain litigation charges | — |  |  | — |  |  | — |  |  | 26 |  |  | — |  |  | 26 |
Acquisition-related items | — |  |  | — |  |  | — |  |  | 283 |  |  | — |  |  | 283 |
Amortization of intangible assets | — |  |  | — |  |  | — |  |  | 1,931 |  |  | — |  |  | 1,931 |
Other expense (income), net | 112 |  |  | 1 |  |  | (18 | ) |  | 12 |  |  | — |  |  | 107 |
Operating (loss) profit | (122 | ) |  | (2 | ) |  | 15 |  |  | 5,400 |  |  | — |  |  | 5,291 |
Interest income | — |  |  | (434 | ) |  | (710 | ) |  | (464 | ) |  | 1,177 |  |  | (431 | )
Interest expense | 25 |  |  | 138 |  |  | 10 |  |  | 2,390 |  |  | (1,177 | ) |  | 1,386 |
Interest expense (income), net | 25 |  |  | (296 | ) |  | (700 | ) |  | 1,926 |  |  | — |  |  | 955 |
Equity in net (income) loss of subsidiaries | (3,676 | ) |  | (2,043 | ) |  | (2,961 | ) |  | — |  |  | 8,680 |  |  | — |
Income (loss) from operations before income taxes | 3,529 |  |  | 2,337 |  |  | 3,676 |  |  | 3,474 |  |  | (8,680 | ) |  | 4,336 |
Provision (benefit) for income taxes | (9 | ) |  | — |  |  | — |  |  | 807 |  |  | — |  |  | 798 |
Net income | 3,538 |  |  | 2,337 |  |  | 3,676 |  |  | 2,667 |  |  | (8,680 | ) |  | 3,538 |
Other comprehensive (loss) income, net of tax | (684 | ) |  | (102 | ) |  | (684 | ) |  | (684 | ) |  | 1,470 |  |  | (684 | )
Total comprehensive income (loss) | $ | 2,854 |  |  | $ | 2,235 |  |  | $ | 2,992 |  |  | $ | 1,983 |  |  | $ | (7,210 | ) |  | $ | 2,854 |
Consolidating Statement of Comprehensive Income Fiscal Year Ended April 24, 2015 CIFSA Senior Notes
(in millions) | Medtronic plc |  | CIFSA |  | CIFSA Subsidiary Guarantors |  | Subsidiary Non-guarantors |  | Consolidating Adjustments |  | Total
Net sales | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 20,261 |  |  | $ | — |  |  | $ | 20,261 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of products sold | — |  |  | — |  |  | — |  |  | 6,309 |  |  | — |  |  | 6,309 |
Research and development expense | — |  |  | — |  |  | — |  |  | 1,640 |  |  | — |  |  | 1,640 |
Selling, general, and administrative expense | 1 |  |  | — |  |  | 21 |  |  | 6,882 |  |  | — |  |  | 6,904 |
Special charge (gain), net | — |  |  | — |  |  | — |  |  | (38 | ) |  | — |  |  | (38 | )
Restructuring charges, net | — |  |  | — |  |  | — |  |  | 237 |  |  | — |  |  | 237 |
Certain litigation charges | — |  |  | — |  |  | — |  |  | 42 |  |  | — |  |  | 42 |
Acquisition-related items | — |  |  | — |  |  | — |  |  | 550 |  |  | — |  |  | 550 |
Amortization of intangible assets | — |  |  | — |  |  | — |  |  | 733 |  |  | — |  |  | 733 |
Other expense (income), net | 103 |  |  | — |  |  | 26 |  |  | (11 | ) |  | — |  |  | 118 |
Operating (loss) profit | (104 | ) |  | — |  |  | (47 | ) |  | 3,917 |  |  | — |  |  | 3,766 |
Interest income | — |  |  | (149 | ) |  | (170 | ) |  | (386 | ) |  | 319 |  |  | (386 | )
Interest expense | — |  |  | 29 |  |  | — |  |  | 956 |  |  | (319 | ) |  | 666 |
Interest expense (income), net | — |  |  | (120 | ) |  | (170 | ) |  | 570 |  |  | — |  |  | 280 |
Equity in net (income) loss of subsidiaries | (2,790 | ) |  | 1,085 |  |  | (2,667 | ) |  | — |  |  | 4,372 |  |  | — |
Income (loss) from operations before income taxes | 2,686 |  |  | (965 | ) |  | 2,790 |  |  | 3,347 |  |  | (4,372 | ) |  | 3,486 |
Provision (benefit) for income taxes | 11 |  |  | — |  |  | — |  |  | 800 |  |  | — |  |  | 811 |
Net income | 2,675 |  |  | (965 | ) |  | 2,790 |  |  | 2,547 |  |  | (4,372 | ) |  | 2,675 |
Other comprehensive (loss) income, net of tax | (587 | ) |  | 200 |  |  | (587 | ) |  | (587 | ) |  | 974 |  |  | (587 | )
Total comprehensive income (loss) | $ | 2,088 |  |  | $ | (765 | ) |  | $ | 2,203 |  |  | $ | 1,960 |  |  | $ | (3,398 | ) |  | $ | 2,088 |
Condensed Consolidating Balance Sheet April 28, 2017 CIFSA Senior Notes
(in millions) | Medtronic plc |  | CIFSA |  | CIFSA Subsidiary Guarantors |  | Subsidiary Non-guarantors |  | Consolidating Adjustments |  | Total
ASSETS |  |  |  |  |  |  |  |  |  |  |
Current assets: |  |  |  |  |  |  |  |  |  |  |
Cash and cash equivalents | $ | — |  |  | $ | 33 |  |  | $ | 5 |  |  | $ | 4,929 |  |  | $ | — |  |  | $ | 4,967 |
Investments | — |  |  | — |  |  | — |  |  | 8,741 |  |  | — |  |  | 8,741 |
Accounts receivable, net | — |  |  | — |  |  | — |  |  | 5,591 |  |  | — |  |  | 5,591 |
Inventories, net | — |  |  | — |  |  | — |  |  | 3,338 |  |  | — |  |  | 3,338 |
Intercompany receivable | 63 |  |  | — |  |  | 60 |  |  | 12 |  |  | (135 | ) |  | — |
Prepaid expenses and other current assets | 10 |  |  | — |  |  | — |  |  | 1,855 |  |  | — |  |  | 1,865 |
Current assets held for sale | — |  |  | — |  |  | — |  |  | 371 |  |  | — |  |  | 371 |
Total current assets | 73 |  |  | 33 |  |  | 65 |  |  | 24,837 |  |  | (135 | ) |  | 24,873 |
Property, plant and equipment, net | — |  |  | — |  |  | — |  |  | 4,361 |  |  | — |  |  | 4,361 |
Goodwill | — |  |  | — |  |  | — |  |  | 38,515 |  |  | — |  |  | 38,515 |
Other intangible assets, net | — |  |  | — |  |  | — |  |  | 23,407 |  |  | — |  |  | 23,407 |
Tax assets | — |  |  | — |  |  | — |  |  | 1,509 |  |  | — |  |  | 1,509 |
Investment in subsidiaries | 55,833 |  |  | 31,033 |  |  | 51,294 |  |  | — |  |  | (138,160 | ) |  | — |
Intercompany loans receivable | 3,000 |  |  | 2,978 |  |  | 17,383 |  |  | 17,260 |  |  | (40,621 | ) |  | — |
Other assets | — |  |  | — |  |  | — |  |  | 1,232 |  |  | — |  |  | 1,232 |
Noncurrent assets held for sale | — |  |  | — |  |  | — |  |  | 5,919 |  |  | — |  |  | 5,919 |
Total assets | $ | 58,906 |  |  | $ | 34,044 |  |  | $ | 68,742 |  |  | $ | 117,040 |  |  | $ | (178,916 | ) |  | $ | 99,816 |
LIABILITIES AND EQUITY |  |  |  |  |  |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |  |  |  |  |  |
Current debt obligations | $ | — |  |  | $ | 1,176 |  |  | $ | 901 |  |  | $ | 5,443 |  |  | $ | — |  |  | $ | 7,520 |
Accounts payable | — |  |  | — |  |  | — |  |  | 1,731 |  |  | — |  |  | 1,731 |
Intercompany payable | 12 |  |  | — |  |  | — |  |  | 123 |  |  | (135 | ) |  | — |
Accrued compensation | 9 |  |  | — |  |  | — |  |  | 1,851 |  |  | — |  |  | 1,860 |
Accrued income taxes | 13 |  |  | — |  |  | — |  |  | 620 |  |  | — |  |  | 633 |
Other accrued expenses | — |  |  | 23 |  |  | 8 |  |  | 2,411 |  |  | — |  |  | 2,442 |
Current liabilities held for sale | — |  |  | — |  |  | — |  |  | 34 |  |  | — |  |  | 34 |
Total current liabilities | 34 |  |  | 1,199 |  |  | 909 |  |  | 12,213 |  |  | (135 | ) |  | 14,220 |
Long-term debt | — |  |  | 2,133 |  |  | 1,842 |  |  | 21,946 |  |  | — |  |  | 25,921 |
Accrued compensation and retirement benefits | — |  |  | — |  |  | — |  |  | 1,641 |  |  | — |  |  | 1,641 |
Accrued income taxes | 10 |  |  | — |  |  | — |  |  | 2,395 |  |  | — |  |  | 2,405 |
Intercompany loans payable | 8,568 |  |  | 1,369 |  |  | 17,161 |  |  | 13,523 |  |  | (40,621 | ) |  | — |
Deferred tax liabilities | — |  |  | — |  |  | — |  |  | 2,978 |  |  | — |  |  | 2,978 |
Other liabilities | — |  |  | — |  |  | — |  |  | 1,515 |  |  | — |  |  | 1,515 |
Noncurrent liabilities held for sale | — |  |  | — |  |  | — |  |  | 720 |  |  | — |  |  | 720 |
Total liabilities | 8,612 |  |  | 4,701 |  |  | 19,912 |  |  | 56,931 |  |  | (40,756 | ) |  | 49,400 |
Shareholders’ equity | 50,294 |  |  | 29,343 |  |  | 48,830 |  |  | 59,987 |  |  | (138,160 | ) |  | 50,294 |
Noncontrolling interests | — |  |  | — |  |  | — |  |  | 122 |  |  | — |  |  | 122 |
Total equity | 50,294 |  |  | 29,343 |  |  | 48,830 |  |  | 60,109 |  |  | (138,160 | ) |  | 50,416 |
Total liabilities and equity | $ | 58,906 |  |  | $ | 34,044 |  |  | $ | 68,742 |  |  | $ | 117,040 |  |  | $ | (178,916 | ) |  | $ | 99,816 |
Condensed Consolidating Balance Sheet April 29, 2016 CIFSA Senior Notes
(in millions) | Medtronic plc |  | CIFSA |  | CIFSA Subsidiary Guarantors |  | Subsidiary Non-guarantors |  | Consolidating Adjustments |  | Total
ASSETS |  |  |  |  |  |  |  |  |  |  |
Current assets: |  |  |  |  |  |  |  |  |  |  |
Cash and cash equivalents | $ | — |  |  | $ | 208 |  |  | $ | — |  |  | $ | 2,668 |  |  | $ | — |  |  | $ | 2,876 |
Investments | — |  |  | — |  |  | — |  |  | 9,758 |  |  | — |  |  | 9,758 |
Accounts receivable, net | — |  |  | — |  |  | — |  |  | 5,562 |  |  | — |  |  | 5,562 |
Inventories, net | — |  |  | — |  |  | — |  |  | 3,473 |  |  | — |  |  | 3,473 |
Intercompany receivable | 403 |  |  | — |  |  | 61 |  |  | — |  |  | (464 | ) |  | — |
Prepaid expenses and other current assets | 24 |  |  | — |  |  | — |  |  | 1,907 |  |  | — |  |  | 1,931 |
Total current assets | 427 |  |  | 208 |  |  | 61 |  |  | 23,368 |  |  | (464 | ) |  | 23,600 |
Property, plant and equipment, net | — |  |  | — |  |  | 1 |  |  | 4,840 |  |  | — |  |  | 4,841 |
Goodwill | — |  |  | — |  |  | — |  |  | 41,500 |  |  | — |  |  | 41,500 |
Other intangible assets, net | — |  |  | — |  |  | — |  |  | 26,899 |  |  | — |  |  | 26,899 |
Tax assets | — |  |  | — |  |  | — |  |  | 1,383 |  |  | — |  |  | 1,383 |
Investment in subsidiaries | 52,608 |  |  | 36,476 |  |  | 48,375 |  |  | — |  |  | (137,459 | ) |  | — |
Intercompany loans receivable | 3,000 |  |  | 8,253 |  |  | 11,465 |  |  | 27,724 |  |  | (50,442 | ) |  | — |
Other assets | — |  |  | — |  |  | — |  |  | 1,421 |  |  | — |  |  | 1,421 |
Total assets | $ | 56,035 |  |  | $ | 44,937 |  |  | $ | 59,902 |  |  | $ | 127,135 |  |  | $ | (188,365 | ) |  | $ | 99,644 |
LIABILITIES AND EQUITY |  |  |  |  |  |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |  |  |  |  |  |
Current debt obligations | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 993 |  |  | $ | — |  |  | $ | 993 |
Accounts payable | — |  |  | — |  |  | — |  |  | 1,709 |  |  | — |  |  | 1,709 |
Intercompany payable | — |  |  | — |  |  | — |  |  | 464 |  |  | (464 | ) |  | — |
Accrued compensation | 32 |  |  | — |  |  | — |  |  | 1,680 |  |  | — |  |  | 1,712 |
Accrued income taxes | 11 |  |  | — |  |  | — |  |  | 555 |  |  | — |  |  | 566 |
Other accrued expenses | 1 |  |  | 24 |  |  | — |  |  | 2,160 |  |  | — |  |  | 2,185 |
Total current liabilities | 44 |  |  | 24 |  |  | — |  |  | 7,561 |  |  | (464 | ) |  | 7,165 |
Long-term debt | — |  |  | 3,382 |  |  | — |  |  | 26,727 |  |  | — |  |  | 30,109 |
Accrued compensation and retirement benefits | — |  |  | — |  |  | — |  |  | 1,759 |  |  | — |  |  | 1,759 |
Accrued income taxes | 10 |  |  | — |  |  | — |  |  | 2,893 |  |  | — |  |  | 2,903 |
Intercompany loans payable | 3,918 |  |  | 14,689 |  |  | 14,298 |  |  | 17,537 |  |  | (50,442 | ) |  | — |
Deferred tax liabilities | — |  |  | — |  |  | — |  |  | 3,729 |  |  | — |  |  | 3,729 |
Other liabilities | — |  |  | — |  |  | — |  |  | 1,916 |  |  | — |  |  | 1,916 |
Total liabilities | 3,972 |  |  | 18,095 |  |  | 14,298 |  |  | 62,122 |  |  | (50,906 | ) |  | 47,581 |
Total equity | 52,063 |  |  | 26,842 |  |  | 45,604 |  |  | 65,013 |  |  | (137,459 | ) |  | 52,063 |
Total liabilities and equity | $ | 56,035 |  |  | $ | 44,937 |  |  | $ | 59,902 |  |  | $ | 127,135 |  |  | $ | (188,365 | ) |  | $ | 99,644 |
Condensed Consolidating Statement of Cash Flows Fiscal Year Ended April 28, 2017 CIFSA Senior Notes
(in millions) | Medtronic plc |  | CIFSA |  | CIFSA Subsidiary Guarantors |  | Subsidiary Non-guarantors |  | Consolidating Adjustments |  | Total
Operating Activities: |  |  |  |  |  |  |  |  |  |  |
Net cash provided by operating activities | $ | 842 |  |  | $ | 1,904 |  |  | $ | 302 |  |  | $ | 5,829 |  |  | $ | (1,997 | ) |  | $ | 6,880 |
Investing Activities: |  |  |  |  |  |  |  |  |  |  |
Acquisitions, net of cash acquired | — |  |  | — |  |  | — |  |  | (1,324 | ) |  | — |  |  | (1,324 | )
Additions to property, plant, and equipment | — |  |  | — |  |  | — |  |  | (1,254 | ) |  | — |  |  | (1,254 | )
Purchases of investments | — |  |  | — |  |  | — |  |  | (4,371 | ) |  | — |  |  | (4,371 | )
Sales and maturities of investments | — |  |  | — |  |  | — |  |  | 5,356 |  |  | — |  |  | 5,356 |
Net (increase) decrease in intercompany loans receivable | — |  |  | 5,275 |  |  | (5,911 | ) |  | 3,956 |  |  | (3,320 | ) |  | — |
Capital contributions paid | — |  |  | (537 | ) |  | — |  |  | — |  |  | 537 |  |  | — |
Other investing activities, net | — |  |  | — |  |  | — |  |  | 22 |  |  | — |  |  | 22 |
Net cash (used in) provided by investing activities | — |  |  | 4,738 |  |  | (5,911 | ) |  | 2,385 |  |  | (2,783 | ) |  | (1,571 | )
Financing Activities: |  |  |  |  |  |  |  |  |  |  |
Acquisition-related contingent consideration | — |  |  | — |  |  | — |  |  | (69 | ) |  | — |  |  | (69 | )
Change in current debt obligations, net | — |  |  | — |  |  | 901 |  |  | 5 |  |  | — |  |  | 906 |
Repayment of short-term borrowings (maturities greater than 90 days) | — |  |  | — |  |  | — |  |  | (2 | ) |  | — |  |  | (2 | )
Proceeds from short-term borrowings (maturities greater than 90 days) | — |  |  | — |  |  | — |  |  | 12 |  |  | — |  |  | 12 |
Issuance of long-term debt | — |  |  | — |  |  | 1,850 |  |  | 290 |  |  | — |  |  | 2,140 |
Payments on long-term debt | — |  |  | — |  |  | — |  |  | (863 | ) |  | — |  |  | (863 | )
Dividends to shareholders | (2,376 | ) |  | — |  |  | — |  |  | — |  |  | — |  |  | (2,376 | )
Issuance of ordinary shares | 428 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 428 |
Repurchase of ordinary shares | (3,544 | ) |  | — |  |  | — |  |  | — |  |  | — |  |  | (3,544 | )
Net intercompany loan borrowings (repayments) | 4,650 |  |  | (6,817 | ) |  | 2,863 |  |  | (4,016 | ) |  | 3,320 |  |  | — |
Intercompany dividend paid | — |  |  | — |  |  | — |  |  | (1,997 | ) |  | 1,997 |  |  | — |
Capital contributions received | — |  |  | — |  |  | — |  |  | 537 |  |  | (537 | ) |  | — |
Other financing activities | — |  |  | — |  |  | — |  |  | 85 |  |  | — |  |  | 85 |
Net cash (used in) provided by financing activities | (842 | ) |  | (6,817 | ) |  | 5,614 |  |  | (6,018 | ) |  | 4,780 |  |  | (3,283 | )
Effect of exchange rate changes on cash and cash equivalents | — |  |  | — |  |  | — |  |  | 65 |  |  | — |  |  | 65 |
Net change in cash and cash equivalents | — |  |  | (175 | ) |  | 5 |  |  | 2,261 |  |  | — |  |  | 2,091 |
Cash and cash equivalents at beginning of period | — |  |  | 208 |  |  | — |  |  | 2,668 |  |  | — |  |  | 2,876 |
Cash and cash equivalents at end of period | $ | — |  |  | $ | 33 |  |  | $ | 5 |  |  | $ | 4,929 |  |  | $ | — |  |  | $ | 4,967 |
Condensed Consolidating Statement of Cash Flows Fiscal Year Ended April 29, 2016 CIFSA Senior Notes
(in millions) | Medtronic plc |  | CIFSA |  | CIFSA Subsidiary Guarantors |  | Subsidiary Non-guarantors |  | Consolidating Adjustments |  | Total
Operating Activities: |  |  |  |  |  |  |  |  |  |  |
Net cash provided by operating activities | $ | 297 |  |  | $ | 4,208 |  |  | $ | 604 |  |  | $ | 4,114 |  |  | $ | (4,005 | ) |  | $ | 5,218 |
Investing Activities: |  |  |  |  |  |  |  |  |  |  |
Acquisitions, net of cash acquired | — |  |  | — |  |  | — |  |  | (1,266 | ) |  | 53 |  |  | (1,213 | )
Additions to property, plant, and equipment | — |  |  | — |  |  | — |  |  | (1,046 | ) |  | — |  |  | (1,046 | )
Purchases of investments | — |  |  | — |  |  | — |  |  | (5,406 | ) |  | — |  |  | (5,406 | )
Sales and maturities of investments | — |  |  | — |  |  | — |  |  | 9,924 |  |  | — |  |  | 9,924 |
Net (increase) decrease in intercompany loans receivable | — |  |  | (8,193 | ) |  | (164 | ) |  | (3,302 | ) |  | 11,659 |  |  | — |
Sale of subsidiaries | — |  |  | — |  |  | 53 |  |  | — |  |  | (53 | ) |  | — |
Capital contributions paid | — |  |  | (720 | ) |  | (4,959 | ) |  | — |  |  | 5,679 |  |  | — |
Other investing activities, net | — |  |  | — |  |  | — |  |  | (14 | ) |  | — |  |  | (14 | )
Net cash (used in) provided by investing activities | — |  |  | (8,913 | ) |  | (5,070 | ) |  | (1,110 | ) |  | 17,338 |  |  | 2,245 |
Financing Activities: |  |  |  |  |  |  |  |  |  |  |
Acquisition-related contingent consideration | — |  |  | — |  |  | — |  |  | (22 | ) |  | — |  |  | (22 | )
Change in current debt obligations, net | — |  |  | — |  |  | — |  |  | 7 |  |  | — |  |  | 7 |
Repayment of short-term borrowings (maturities greater than 90 days) | — |  |  | — |  |  | (139 | ) |  | — |  |  | — |  |  | (139 | )
Proceeds from short-term borrowings (maturities greater than 90 days) | — |  |  | — |  |  | 139 |  |  | — |  |  | — |  |  | 139 |
Payments on long-term debt | — |  |  | (2,121 | ) |  | — |  |  | (3,011 | ) |  | — |  |  | (5,132 | )
Dividends to shareholders | (2,139 | ) |  | — |  |  | — |  |  | — |  |  | — |  |  | (2,139 | )
Issuance of ordinary shares | 491 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 491 |
Repurchase of ordinary shares | (2,830 | ) |  | — |  |  | — |  |  | — |  |  | — |  |  | (2,830 | )
Net intercompany loan borrowings (repayments) | 3,918 |  |  | 6,306 |  |  | 4,296 |  |  | (2,861 | ) |  | (11,659 | ) |  | — |
Intercompany dividend paid | — |  |  | — |  |  | — |  |  | (4,005 | ) |  | 4,005 |  |  | — |
Capital contributions received | — |  |  | — |  |  | — |  |  | 5,679 |  |  | (5,679 | ) |  | — |
Other financing activities | — |  |  | — |  |  | — |  |  | 82 |  |  | — |  |  | 82 |
Net cash (used in) provided by financing activities | (560 | ) |  | 4,185 |  |  | 4,296 |  |  | (4,131 | ) |  | (13,333 | ) |  | (9,543 | )
Effect of exchange rate changes on cash and cash equivalents | — |  |  | — |  |  | — |  |  | 113 |  |  | — |  |  | 113 |
Net change in cash and cash equivalents | (263 | ) |  | (520 | ) |  | (170 | ) |  | (1,014 | ) |  | — |  |  | (1,967 | )
Cash and cash equivalents at beginning of period | 263 |  |  | 728 |  |  | 170 |  |  | 3,682 |  |  | — |  |  | 4,843 |
Cash and cash equivalents at end of period | $ | — |  |  | $ | 208 |  |  | $ | — |  |  | $ | 2,668 |  |  | $ | — |  |  | $ | 2,876 |
Condensed Consolidating Statement of Cash Flows Fiscal Year Ended April 24, 2015 CIFSA Senior Notes
(in millions) | Medtronic plc |  | CIFSA |  | CIFSA Subsidiary Guarantors |  | Subsidiary Non-guarantors |  | Consolidating Adjustments |  | Total
Operating Activities: |  |  |  |  |  |  |  |  |  |  |
Net cash provided by operating activities | $ | 26 |  |  | $ | 1,238 |  |  | $ | 142 |  |  | $ | 4,596 |  |  | $ | (1,100 | ) |  | $ | 4,902 |
Investing Activities: |  |  |  |  |  |  |  |  |  |  |
Acquisitions, net of cash acquired | (9,700 | ) |  | 440 |  |  | — |  |  | (5,624 | ) |  | — |  |  | (14,884 | )
Additions to property, plant, and equipment | — |  |  | — |  |  | (1 | ) |  | (570 | ) |  | — |  |  | (571 | )
Purchases of investments | — |  |  | — |  |  | — |  |  | (7,582 | ) |  | — |  |  | (7,582 | )
Sales and maturities of investments | — |  |  | — |  |  | — |  |  | 5,890 |  |  | — |  |  | 5,890 |
Net (increase) decrease in intercompany loans receivable | — |  |  | (59 | ) |  | 29 |  |  | (10,626 | ) |  | 10,656 |  |  | — |
Capital contributions paid | — |  |  | (937 | ) |  | — |  |  | — |  |  | 937 |  |  | — |
Other investing activities, net | — |  |  | — |  |  | — |  |  | 89 |  |  | — |  |  | 89 |
Net cash (used in) provided by investing activities | (9,700 | ) |  | (556 | ) |  | 28 |  |  | (18,423 | ) |  | 11,593 |  |  | (17,058 | )
Financing Activities: |  |  |  |  |  |  |  |  |  |  |
Acquisition-related contingent consideration | — |  |  | — |  |  | — |  |  | (85 | ) |  | — |  |  | (85 | )
Change in current debt obligations, net | — |  |  | — |  |  | — |  |  | (1 | ) |  | — |  |  | (1 | )
Repayment of short-term borrowings (maturities greater than 90 days) | — |  |  | — |  |  | (150 | ) |  | — |  |  | — |  |  | (150 | )
Proceeds from short-term borrowings (maturities greater than 90 days) | — |  |  | — |  |  | 150 |  |  | — |  |  | — |  |  | 150 |
Issuance of long-term debt | — |  |  | — |  |  | — |  |  | 19,942 |  |  | — |  |  | 19,942 |
Payments on long-term debt | — |  |  | (51 | ) |  | — |  |  | (1,217 | ) |  | — |  |  | (1,268 | )
Dividends to shareholders | (435 | ) |  | — |  |  | — |  |  | (902 | ) |  | — |  |  | (1,337 | )
Issuance of ordinary shares | 172 |  |  | — |  |  | — |  |  | 477 |  |  | — |  |  | 649 |
Repurchase of ordinary shares | (300 | ) |  | — |  |  | — |  |  | (1,620 | ) |  | — |  |  | (1,920 | )
Net intercompany loan borrowings (repayments) | 10,500 |  |  | 97 |  |  | — |  |  | 59 |  |  | (10,656 | ) |  | — |
Intercompany dividend paid | — |  |  | — |  |  | — |  |  | (1,100 | ) |  | 1,100 |  |  | — |
Capital contributions received | — |  |  | — |  |  | — |  |  | 937 |  |  | (937 | ) |  | — |
Other financing activities | — |  |  | — |  |  | — |  |  | (31 | ) |  | — |  |  | (31 | )
Net cash (used in) provided by financing activities | 9,937 |  |  | 46 |  |  | — |  |  | 16,459 |  |  | (10,493 | ) |  | 15,949 |
Effect of exchange rate changes on cash and cash equivalents | — |  |  | — |  |  | — |  |  | (353 | ) |  | — |  |  | (353 | )
Net change in cash and cash equivalents | 263 |  |  | 728 |  |  | 170 |  |  | 2,279 |  |  | — |  |  | 3,440 |
Cash and cash equivalents at beginning of period | — |  |  | — |  |  | — |  |  | 1,403 |  |  | — |  |  | 1,403 |
Cash and cash equivalents at end of period | $ | 263 |  |  | $ | 728 |  |  | $ | 170 |  |  | $ | 3,682 |  |  | $ | — |  |  | $ | 4,843 |

X
- References No definition available. + Details
Name: | us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 10 -Section S99 -Paragraph 3 -Subparagraph (SX 210.7-05(c)(Schedule II)) -URI http://asc.fasb.org/extlink&oid=6879921&loc=d3e569147-122900 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=96868048&loc=d3e5283-111683 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 2 -Subparagraph (SX 210.9-06) -URI http://asc.fasb.org/extlink&oid=6882215&loc=d3e537971-122884 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 10 -Section S99 -Paragraph 6 -Subparagraph (SX 210.5-04(c)(Schedule I)) -URI http://asc.fasb.org/extlink&oid=27047687&loc=d3e5864-122674 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690 + Details
Name: | us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration